John holds a BSc and a Ph.D. in physiology, both from the University of London. After a postdoctorate position at the London Hospital Medical School, John joined the CNS team at May & Baker (then a division of Rhone Poulenc) in 1985. In 1988 he co-founded a startup CRO (Campbell Charles Associates), moving on in 1992 to be Clinical Research Director at Bios and then again in 1996 to join IBAH (later Omnicare Clinical Research, now Theorem) where he held a number of positions, including Vice President of International Business Development and Regional General Manager for Northern Europe.
John joined PAREXEL in 2001 to head a customer business unit and moved to HQ in Boston early in 2002 to run the global sales organization for the Clinical Research Services division. He joined AstraZeneca in 2004 to head Global Clinical Outsourcing and then joined the newly formed Business Development team at AstraZeneca in January 2007. He has held a number of roles as the Business Development team has evolved and is currently the Head of Business Operations for BD, a role which encompasses most of the back-office functions for BD in addition to leading the due diligence team. John is also responsible for coordinating divestment activity at AstraZeneca and is one of the divestment transaction leads, most recently completing the divestment of US rights for Entocort to Perrigo and ex-US rights to Tillotts Pharma.
Steven Gurney — Principal Associate. Chartered (UK), European and Registered (AU, NZ) Patent Attorney.
Steven specialises in small molecule pharmaceutical patents with experience gained working both in-house and in private practice. He takes a collaborative approach, understanding his clients’ commercial drivers to deliver relevant, pragmatic and actionable advice. Steven works with pharmaceutical companies, universities and start-ups in the fields of small molecule medicines, general chemistry and medical devices. Steven provides strategic advice to his clients, advising on freedom to operate (FTO), due diligence, advice, opposition, and litigation. He is also experienced in drafting pharmaceutical patent applications and also manages the resultant patent portfolios including global prosecution.
Will James is an intellectual property lawyer who advises clients on IP issues in a wide range of technical industries. His particular expertise is in advising on patent issues (including SPCs) in the biotech and pharmaceutical sectors, where he has advised on IP issues in a number of core technologies including antibody engineering systems (transgenic mice and antibody phage display), DNA arrays and sequencing technology, reverse genetics, stem cells and erythropoietin litigation. Will advises clients on commercial issues and IP licensing as well as due diligence, freedom to operate and IP strategy. He has been involved in a number of multi-jurisdictional commercial matters including complex worldwide securitisations of future patent royalty streams.
Will is listed as an ‘IP Star’ by Managing Intellectual Property and in Legal 500. He is also listed as an expert by Who’s Who Legal for patents and for life sciences.
Will was also included in the LMG Life Sciences Guide as a ‘Life Sciences Star’.
Carl Jessop has been a Due Diligence Director for AstraZeneca for nearly nine years, participating in many successful deals including the Pearl acquisition as well as the original BMS deal for the diabetes products, OnglyzaTM, FarxigaTM and NaloxegolTM from Nektar. More recently he worked on the acquisition of the Almirall respiratory products and the Innate Pharma oncology deal. Carl has a BSC (Hons) from the University of Bath and had previously worked for a number of life science and pharmaceutical companies in R&D and as a GLP auditor/manager for 17 years prior to joining AZ. He joined the Global Compliance Management Group at AZ in 2004 before moving on to Business Development two years later. Carl is a Fellow of the Research Quality Association and a member of the Pharmaceutical licensing group.
Dr. Mike Myers has spent 30 years in the industry contributing to the discovery and development of new drugs. He has led drug discovery teams in the pursuit of innovative treatments for cancer, CNS, infectious and cardiovascular diseases. Across these areas of significant need, Dr. Myers has contributed as an inventor on more than 35 patents. Dr. Myers has also led efforts in evaluating new lead generation technologies, predictive ADMET and computational chemistry approaches, and led a significant effort at Lilly to optimize lead generation processes in early drug discovery. Nearly 12 years ago, Dr. Myers moved from his drug discovery role to Senior Director of Project Management and he was engaged in project and portfolio management. Currently, Mike’s main responsibilities within the External Innovation team at Eli Lilly & Company includes leading scientific due diligence activities in support of in-license/acquisition, out-license and strategic partnering activities.